Serious adverse events reported in the COPE trial

Sep 06, 2014

20 likes | 172 Views

Supplemental data. Serious adverse events reported in the COPE trial. Abbreviations: Beni=benidipine , ARB =angiotensin receptor blocker, BB = Î²- blocker, TD = thiazide diuretic, Data are shown as number of patients (%). Supplemental data. Adverse events reported in the COPE trial.

Share Presentation

Embed Code

Link

data
beni benidipine
supplemental data
bb blocker
adverse events reported
arb angiotensin receptor blocker

flavio

Download Presentation

Serious adverse events reported in the COPE trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental data Seriousadverseevents reported in the COPE trial Abbreviations: Beni=benidipine , ARB =angiotensin receptor blocker, BB = β-blocker, TD = thiazide diuretic, Data are shown as number of patients (%).
Supplemental data Adverseevents reported in the COPE trial Abbreviations: ALT=alanine aminotransferase, Beni=benidipine , ARB =angiotensin receptor blocker, BB = β-blocker, TD = thiazide diuretic, Data are shown as number of patients (%).

Adverse Drug Events

Adverse Drug Events . Judith Coombes Neil Cottrell School of Pharmacy, University of Queensland. Objectives.

1.38k views • 35 slides

Adverse Events and Serious Adverse Events

Adverse Events and Serious Adverse Events. Office of Research Education and Regulatory Management. Objectives. Recognize Adverse Events and serious adverse events Review FDA inspection findings related to adverse events Review regulations related to adverse events

1.54k views • 36 slides

Serious Adverse Events

GCP Workshop: Ethics Committee Members. Serious Adverse Events. C.Adithan. Objectives. To make the EC members understand the importance of adverse event (AE) differences between AE and ADR importance of serious adverse event (SAE) regulatory requirements in reporting SAE

1.92k views • 23 slides

Adverse Drug Events

Adverse Drug Events. Howard Shaps, MD, MBA Medical Director Health Care Excel February 27, 2013. Overview. Definitions Statistics and Facts Prevention and Detection Electronic Health Records and Meaningful Use Medication Reconciliation Compliance Pharmacist Involvement.

1.14k views • 75 slides

Monitoring Adverse Events in Surgery

Monitoring Adverse Events in Surgery. Steve Gallivan Clinical OR Unit University College London. Principal Collaborators. Jocelyn Lovegrove (Ex-CORU) Chris Sherlaw-Johnson (CORU) Tom Treasure (Cardiac Surgeon) Jaroslav Stark (Paediatric Cardiac Surgeon)

449 views • 29 slides

Serious Adverse Events & Reporting Victoria Wilde Drug Safety Assistant

Serious Adverse Events & Reporting Victoria Wilde Drug Safety Assistant. 1. What is a serious adverse event? (SAE) 2. Where does our event information come from? 3. How do we process an SAE? 4. MedDRA coding 5. Final points. Overview. An event is serious if it results in. Death

434 views • 19 slides

Serious Adverse Events and Reactions (SAEARs) management

Serious Adverse Events and Reactions (SAEARs) management. 21 October 2010 Dr Christiane Niederlaender. Overview. SAEARs systems required at TEs reporting to the HTA an introduction to the severity grading tools internal investigation assessing cases. Definitions - summary. Reactions :

321 views • 18 slides

BADBIR Adverse Events

BADBIR Adverse Events. Collecting data in clinic . Contents. Aim of BADBIR Definition of Adverse Events Adverse events in BADBIR Adverse event recording in hospital case notes Examples of questions to ask patients Conclusion. Aim of BADBIR.

363 views • 12 slides

No-Charge Policy for Serious Adverse Events

An AHA Member Teleconference Series . No-Charge Policy for Serious Adverse Events. No-Charge Policy for Serious Adverse Events. The Experience of the Exempla Health System April 18, 2008, 1:00 pm ET. Featured Speakers

453 views • 22 slides

Serious Adverse Event Reporting

Serious Adverse Event Reporting. Start-up Meeting March 25, 2010 Kingston, ON. Procedures. Using Pfizer Products MUST follow Pfizer SAE reporting policies. SAEs Defined. Any untoward medical occurrence that at any dose results in: Death Is life-threatening

915 views • 16 slides

Adverse Drug Events

Adverse Drug Events. Judith Coombes Neil Cottrell School of Pharmacy, University of Queensland. Objectives.

542 views • 35 slides

SERIOUS ADVERSE EVENTS REPORTING

SERIOUS ADVERSE EVENTS REPORTING. Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth. Overview. Important definitions Review key features of the NMCP Serious Adverse Events (SAE) Reporting Policy Questions and discussion. What is an Adverse Event (AE)?.

812 views • 16 slides

Adverse Events and Serious Adverse Events

Adverse Events and Serious Adverse Events.

675 views • 55 slides

OB Adverse Events

OB Adverse Events. Lynne Hall 3/26/14. Framing. Give us a WIN! Data – GHA vs DCH Dr. John P Horton, Emory Healthcare Looking Ahead. What has gone well?. Data Review. Dr. Horton. Looking Forward. Next call - ???

291 views • 12 slides

Adverse Events

Adverse Events. Shannon Simmons Vanderbilt Human Research Protections Program July 11, 2014. Outline. Review key terms and federal definitions used in the context of adverse event reporting Review federal and local information on adverse event reporting requirements

1.2k views • 42 slides

Results – serious adverse effects

Adverse effects of colorectal cancer screening with fecal occult blood test: a population-based organized program. Joël LACROUTE, Isabelle GENDRE, Jean Marc BOYAVAL, Philippe PERRIN, Bernard DENIS. Association pour le Dépistage du Cancer colorectal en Alsace (ADECA Alsace), Colmar, FRANCE.

159 views • 1 slides

Workshop - Serious Adverse Events and Reactions

Workshop - Serious Adverse Events and Reactions. 25 March 2009. Aims of the workshop . Discuss examples of incidents and determine whether they should be reported to the HTA or not If reportable, determine whether as a Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)

331 views • 14 slides

Adverse Drug Events

Adverse Drug Events. Hasan Shabbir MD Assistant Professor of Medicine Emory Hospital Medicine May 2008. The Burden of Medical Injuries. Medical injuries account for 44,000 - 98,000 deaths per year in the United States

365 views • 24 slides

ADVERSE DRUG EVENTS

ADVERSE DRUG EVENTS. Géza T. Terézhalmy, D.D.S., M.A. Professor and Dean Emeritus School of Dental Medicine Case Western Reserve University Cleveland, Ohio. Adverse Drug Events.

1.43k views • 96 slides

ADVERSE TRANSFUSION EVENTS

ADVERSE TRANSFUSION EVENTS. HEMATOLOGY ROUNDS August 23, 2012 D.K. Towns, MD, FRCPC (Anesthesia) Medical Director Canadian Blood Services Calgary, AB. OVERVIEW OF THE CANADIAN BLOOD SYSTEM. The blood system in Canada is complex. Regulator. Health Canada. Blood Suppliers.

876 views • 67 slides

Falls Reported as Serious and Sentinel Events

Falls Reported as Serious and Sentinel Events Matthew Pitt, Senior Adviser, Reportable Events HQSC Presentation 3 to National Falls Programme Expert Advisory Group meeting 13 July 2012, HQSC. The 50% Rule. From 2007/08 increased by 50% each year to high of 195 in 2010/11

267 views • 13 slides

Adverse Events Reported with the Use of Mazindol in Adult Obese Mexican Patients

Obesity is a pandemic disease. Lifestyle modifications as diet and exercise remain as the first-line intervention for obesity; however, many patients fail to attain adequate weight loss and require drug treatment. Mazindol is a short-term useful agent in the treatment of obesity, whose safety profile has not been analyzed in Mexican population. The current study was performed to investigate the reports of adverse events, received in the supplier laboratory for 8 years (2009-2016) with the purpose of determine potential issues of safety, related to Mazindol (MZ1u00ae). Methods: Adverse events were arranged in frequency tables and stratified by intensity and causality. Subgroups of sex, age and BMI with a higher frequency of side-effects were identified, as well as the main comorbidities and concomitant medications.

73 views • 6 slides

More Related

Serious adverse events reported in the COPE trial

Serious adverse events reported in the COPE trial

Presentation Transcript

Adverse Drug Events

Adverse Events and Serious Adverse Events

Serious Adverse Events

Adverse Drug Events

Monitoring Adverse Events in Surgery

Serious Adverse Events &amp; Reporting Victoria Wilde Drug Safety Assistant

Serious Adverse Events and Reactions (SAEARs) management

BADBIR Adverse Events

No-Charge Policy for Serious Adverse Events

Serious Adverse Event Reporting

Adverse Drug Events

SERIOUS ADVERSE EVENTS REPORTING

Adverse Events and Serious Adverse Events

OB Adverse Events

Adverse Events

Results – serious adverse effects

Workshop - Serious Adverse Events and Reactions

Adverse Drug Events

ADVERSE DRUG EVENTS

ADVERSE TRANSFUSION EVENTS

Falls Reported as Serious and Sentinel Events

Adverse Events Reported with the Use of Mazindol in Adult Obese Mexican Patients

Serious Adverse Events & Reporting Victoria Wilde Drug Safety Assistant